© 2021 MJH Life Sciences and Cure Today. All rights reserved.
© 2021 MJH Life Sciences™ and Cure Today. All rights reserved.
March 16th 2021, 9:00pm
Data from a recent study found that while the risk of developing cancer is 1.74 times greater for individuals born with major birth defects, that risk is highest in childhood but decreases slightly after age 20.
December 1st 2020, 8:36pm
The drug has been approved to treat patients with advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer.
September 21st 2019, 8:00pm
For Thyroid Cancer Awareness Month, here’s a round-up of the latest news and updates in this disease space.
September 5th 2019, 7:00pm
Progress in treating rare cancers represents the most significant oncology advance of last year, ASCO says.
August 30th 2019, 12:00am
A new drug can break the circuit of cancer-causing effects that develop when certain genes fuse.
July 2nd 2019, 6:00pm
Cancer doesn’t discriminate. It doesn’t care what race, gender, ethnicity, sexuality or even age you are. It takes no prisoners. And it certainly did not take me. I continue to remain resilient despite what I’ve been through and despite what still may be on the horizon.
June 7th 2019, 10:00pm
From today’s top entertainers to racial disparities in access to pain treatment, here’s what is making headlines in the cancer space this week.
May 23rd 2019, 12:21am
As a result of what I went through and my never-ending passion for helping others, I believe that my diagnosis happened for a reason – to lead me to a career in patient advocacy.
November 27th 2018, 8:46pm
Survivor diagnosed with second cancer after surgeon spots a lump on her throat while watching TV.
October 15th 2018, 7:06pm
The Food and Drug Administration has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with advanced RET fusion–positive thyroid cancer who require systemic therapy, have progressed on prior treatment, and have no other acceptable alternative treatment options, according to a statement from Loxo Oncology, the developer of the selective RET inhibitor.
Ayvakit Shows Promise for Patients with Gastrointestinal Stomach Tumors With Specific Mutation
FDA Approves Opdivo for the Frontline Treatment of Gastric Cancer
Learning to be a Kinder Person After Cancer